Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab biosimilar - Sichuan Kelun Pharmaceutical Research Institute

Next Previous
Drug Profile

Cetuximab biosimilar - Sichuan Kelun Pharmaceutical Research Institute

Alternative Names: A-140; Cetuximab-N01; KL 140; Recombinant anti-EGFr antibody

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Kelun Pharmaceutical Research Institute
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Colorectal cancer

Most Recent Events

  • 07 Feb 2025 Registered for Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy, Late-stage disease) in China (IV)
  • 07 Feb 2025 Efficacy and adverse events data from a phase III trial in Colorectal cancer released by Sichuan Kelun-Biotech Biopharmaceutical
  • 31 Jan 2024 Cetuximab biosimilar - Sichuan Kelun Pharmaceutical Research Institute is available for licensing as of 31 Jan 2024. https://www.kluspharma.com/contact

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top